Home » Newsletters » BioWorld Science

BioWorld Science

Dec. 7, 2000

View Archived Issues

Roche/deCODE Genetics alliance identifies genetic risk factor for PAOD

NIH-funded research leads to identification of gene related to autism

Genzyme General licenses small molecules with potential in lysosomal storage disease therapy

Xyrem NDA accepted for filing

Belgian group maintains focus on discovering new TxA2 inhibitors related to torasemide

Novel SERM devoid of uterotrophic effects presented at Breast Cancer Symposium

NXY-059 effective in various animal models of stroke and well tolerated in acute stroke patients

Novel series of antiproliferative compounds patented by Schering

Microtubule-stabilizing antitumor agents in the Schering pipeline

NeuroSearch describes new nAChR modulators and their use

D-Mannitol derivatives useful as anti-HIV agents designed at Pharmacor

Synthesis and biological activity of Pfizer's new PDE4 inhibitors

Millennium identifies novel ACE-2 inhibitors for use in cardiovascular disorders

Imidazoline alpha1A-adrenoceptor agonists especially useful in Rx of urinary incontinence

Piperidine and piperazine derivatives useful as CCR5 antagonists

Coulter/Corixa merger update reported

Final analysis of phase I results for BrevaRex presented to American Society of Hematology

Synthetic camptothecin derivative shows potential in AML and other hematological malignancies

Tezacitabine, an antimetabolite nucleoside analogue, assessed in hematological malignancies

Copaxone launched in the U.K.

Data presented at AHS meeting support further development of G-3139 in combination regimens

Mid-November launch in Japan for Allegra

NeoPharm commences phase I/II trial of SS1(dsFv)-PE38

Zanamivir as an effective option for preventing household transmission of the flu

Epimmune licenses Valentis technology for vaccine development

Atrix completes phase III study of 1-month Leuprogel formulation in advanced prostate cancer

RUTH trial expanded to include invasive breast cancer prevention as main objective

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for March 9, 2026.
Cas and effect: Merck’s phase III ripples HIF-2α space
BioWorld
Oddsmakers wasted no time figuring the market chances after Merck & Co. Inc. rolled out data from the phase III Litespark-011 study testing its oral...
Brain’s hidden tau-clearing pathway uncovered
BioWorld Science
Researchers at INSERM and collaborators have identified hypothalamic tanycytes as mediators of tau clearance and shown that their structural and genetic...
News in brief
BioWorld Asia
BioWorld Asia briefs for March 3, 2026
MSD synthesizes α-synuclein PET agents
BioWorld Science
Merck Sharp & Dohme LLC (MSD) has prepared and tested new positron emission tomography (PET) agents for binding and imaging α-synuclein (SNCA) for the diagnosis...